TABLE 2.
Serologic profiles indicative of EBV reactivation found in 10 out of 22 healthy subjects during 15 months of follow-up
| ELISA | Anti-EBV antigen | Follow-up samplea | Resultb for donor
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| B | E | G | H | J | M | O | U | Y | |||
| Euroimmun | EA IgM | 1 | + | − | − | − | + | − | + | − | − |
| 2 | + | − | − | − | + | − | + | − | − | ||
| 3 | + | − | − | − | + | − | + | − | − | ||
| 4 | + | − | − | − | + | − | + | − | − | ||
| 5 | + | − | − | − | + | − | + | − | − | ||
| 6 | − | + | + | − | + | − | − | ||||
| 7 | − | + | − | ||||||||
| Enzygnost Dade-Behring | EBV IgM | 1 | + | + | − | − | + | − | + | − | + |
| 2 | + | + | − | − | + | − | − | − | + | ||
| 3 | + | + | − | − | + | − | + | − | + | ||
| 4 | + | + | − | − | + | − | − | + | + | ||
| 5 | + | + | − | − | + | − | − | − | + | ||
| 6 | + | − | + | − | − | − | + | ||||
| 7 | − | − | + | ||||||||
| EBV IgA | 1 | + | + | + | + | − | + | − | − | − | |
| 2 | + | + | + | + | − | + | − | − | − | ||
| 3 | + | + | + | − | − | + | − | + | − | ||
| 4 | + | + | + | + | − | + | − | + | − | ||
| 5 | + | + | + | + | − | + | − | − | − | ||
| 6 | + | + | − | + | − | − | − | ||||
| 7 | + | − | − | ||||||||
| EBV IgG | 1 | 412 | 189 | 707 | 108 | 188 | 501 | 364 | 196 | 212 | |
| 2 | 75 | 193 | 800 | 87 | 149 | 738 | 339 | 194 | 333 | ||
| 3 | 385 | 178 | 896 | 124 | 162 | 783 | 409 | 189 | 397 | ||
| 4 | 347 | 292 | 648 | 165 | 213 | 923 | 447 | 223 | 416 | ||
| 5 | 197 | 139 | 681 | 188 | 203 | 1,007 | 353 | 125 | 328 | ||
| 6 | 182 | 188 | 201 | 666 | 318 | 274 | 378 | ||||
| 7 | 161 | 289 | 442 | ||||||||
a
Follow-up samples were obtained within a period of 15 months with at least 10 (men) or 12 (women) weeks between two appointments.
b
Results are reported as positive or negative, except for those obtained with EBV IgG, which are given in international units per milliliter. Boldface type is used for titer that are >650 IU/ml, which in the presence of EBV IgA were regarded as indicative of reactivation.